|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Market: Norway
Espicom Business Intelligence Ltd, Oct 2011, Pages: 52
THE PHARMACEUTICAL MARKET: NORWAY - REVIEW
The macroenvironment for the Norwegian pharmaceutical industry is improving. Politically, the centre-left coalition is expected to hold together at least until the general election in September 2013, but the risk of the coalition breaking up has grown. The recession was far less pronounced in Norway than in most other European countries and economic recovery is now strengthening. Legally, laws on intellectual property and patent provision are in line with WTO/TRIPS regulations. However, Norway remains on the USTR’s Watch List in 2011 for concerns over patent protection. Demographically, the population is ageing, increasing demand for pharmaceuticals in the near term.
The introduction of international reference pricing has had a moderating effect on Norwegian pharmaceutical price levels, and a step-price system for off-patent drugs has ensured that prices for all generics have fallen. Important steps towards cost-containment have also been taken for reimbursable pharmaceuticals, including the use of a first-choice system. A report by the Business Research Foundation (SNF) has shown that Norwegian pharmaceutical prices are among the lowest in Western Europe. Therefore, market growth is a result of increased consumption, largely due to the ageing population and the introduction of new drugs on the market. Norway is receptive to new drugs, as long as they are cost-effective and have proven therapeutic benefits.
Although Norway is not part of the European Union, the process for pharmaceutical registration has been aligned to EU regulations. The regulatory reforms made the centralised procedure mandatory for all new active substances, and all drugs in a number of drug categories, including all biotech products. In May 2011, PCI Biotech reported that it had been awarded a BIA grant from the Research Council of Norway for the project “immunological effects of photochemical internalisation – local treatment of cancer with metastasis”. The project will be initiated in the third quarter of 2011, and will run for three years. In November 2010, Clavis Pharma raised funds to progress the products in its pipeline and, in the same month, the company extended its licensing deal with a US-based company for its investigational anti-cancer drug.
ENHANCED STRATEGIC INTELLIGENCE
These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
- The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
Customers who bought this item also bought
The Pharmaceutical Market: Canada
The Pharmaceutical Market: Pakistan
The Pharmaceutical Market: Australia
The Pharmaceutical Market: Israel
The Pharmaceutical Market: Austria
The Pharmaceutical Market: Malaysia
The Pharmaceutical Market: Indonesia
The Pharmaceutical Market: Mexico
The Pharmaceutical Market: Finland
The Pharmaceutical Market: France
|
|
|
|
